Pfizer
PFE
2,818 hedge funds and large institutions have $91.7B invested in Pfizer in 2026 Q2 according to their latest regulatory filings, with 154 funds opening new positions, 1,159 increasing their positions, 1,207 reducing their positions, and 234 closing their positions.
0.65% more ownership
Funds ownership: 66.15% → 66.8% (+0.65%)
4% less repeat investments, than reductions
Existing positions increased: 1,159 | Existing positions reduced: 1,207
10% less call options, than puts
Call options by funds: $2.36B | Put options by funds: $2.61B
5% less funds holding
Funds holding: 2,952 → 2,818 (-134)
13% less capital invested
Capital invested by funds: $106B → $91.7B (-$13.8B)
34% less first-time investments, than exits
New positions opened: 154 | Existing positions closed: 234
55% less funds holding in top 10
Funds holding in top 10: 47 → 21 (-26)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$822M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$175M |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
+$168M |
| 4 |
Goldman Sachs
New York
|
+$154M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$152M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$578M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$400M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$276M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$251M |
| 5 |
Amundi
Paris,
France
|
-$191M |
PFE Hedge Fund Activity: Q2 2026 in Review
2,818 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q2 2026, worth a combined $91.7B — down 13% from $106B a quarter earlier.
Sellers outnumbered buyers: 234 funds closed out of PFE and 154 opened new positions — a net loss of 80 holders — while 1,207 trimmed existing stakes and 1,159 added.
The largest buyer was BlackRock, adding an estimated $822M. The largest seller was Wellington Management Group, cutting an estimated $578M.
- 2,818 institutional investors held Pfizer (PFE) as of Q2 2026, down from 2,952 in Q1 2026.
- Funds reported $91.7B of Pfizer stock for Q2 2026, down 13% quarter-over-quarter.
- 154 funds opened new Pfizer positions in Q2 2026 and 234 closed out, a net change of -80 holders.
- The largest Pfizer buyer in Q2 2026 was BlackRock, an estimated $822M added.
- The largest Pfizer seller in Q2 2026 was Wellington Management Group, an estimated $578M sold.
Based on aggregated 13F filings for Q2 2026.